ALMS

Business Context and Reporting Period

Company: Alumis Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune disorders. Key product candidates include envudeucitinib (envu) for psoriasis and systemic lupus erythematosus, A-005 for neuroinflammatory diseases, and lonigutamab (acquired via merger) for Thyroid Eye Disease.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased from $0 in the prior year periods to $2.1 million (Q3) and $22.1 million (YTD) in 2025. This is driven by a new collaboration agreement with Kaken Pharmaceutical Co., Ltd., which generated $17.4 million in license revenue and $4.7 million in collaboration revenue YTD.
• Expense Increase: Operating expenses rose significantly, with R&D expenses increasing 70% YTD to $303.2 million and G&A expenses increasing 221% YTD to $76.3 million. Increases are attributed to the integration of the ACELYRIN Merger, severance costs, and expanded clinical trial activities.
• Gain on Bargain Purchase: A non-cash gain of $187.9 million was recognized in the nine months ended September 30, 2025, resulting from the ACELYRIN Merger where the fair value of net assets acquired exceeded the purchase consideration.
• Net Loss Reduction (YTD): Despite higher operating expenses, the net loss for the nine months ended September 30, 2025, decreased to $(150.4) million from $(199.5) million in the prior year, primarily due to the $187.9 million bargain purchase gain and an $8.6 million income tax benefit.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities of $377.7 million are sufficient to fund operations for at least 12 months from the filing date. The company expects to incur substantial losses for the foreseeable future and will need to raise additional capital.
• Merger Integration: The company completed the ACELYRIN Merger in May 2025, acquiring lonigutamab. Integration costs and severance obligations (estimated at $13.5 million total) are impacting current expenses.
• Clinical Milestones: The company expects topline results for the Phase 3 ONWARD clinical program for envu in psoriasis in early Q1 2026 and for the Phase 2b trial in systemic lupus erythematosus in Q3 2026.
• Legal Contingencies: Alumis assumed a pending federal securities class action lawsuit against ACELYRIN regarding disclosures related to a Phase 2b trial of izokibep. The company has not accrued a liability as the outcome is uncertain and not reasonably estimable.
• Risk Factors: Key risks include the failure of clinical trials, inability to secure regulatory approval, dependence on third-party manufacturers, and the need for significant additional financing.

Investor Verification Checklist

• Merger Accounting: Verify the preliminary purchase price allocation for the ACELYRIN Merger, specifically the $51.0 million valuation of the acquired IPR&D intangible asset and the $187.9 million gain on bargain purchase.
• Revenue Recognition: Review the terms of the Kaken Pharmaceutical collaboration agreement to understand the timing of future revenue recognition for the $20.0 million upfront payment and subsequent development cost reimbursements.
• Cash Burn Rate: Assess the sustainability of the current cash position ($377.7 million) against the reported operating cash outflow of $297.6 million for the nine months ended September 30, 2025.
• Severance Obligations: Monitor the recognition of the estimated $13.5 million severance liability related to the ACELYRIN Merger over the coming year.
• Legal Proceedings: Track the status of the pending securities class action lawsuit against ACELYRIN for potential future accruals or settlements.